A. Marachelian

发表

Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report From NANT Consortium

S. Groshen, J. Maris, K. Matthay, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of Whole‐Body Radiation Dose on Response and Toxicity in Patients With Neuroblastoma After Therapy With 131I‐Metaiodobenzylguanidine (MIBG)

L. Nardo, R. Hawkins, K. Matthay, 2016, Pediatric blood & cancer.

Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial.

Rachel A. Kudgus, S. Groshen, R. Hawkins, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparative pharmacokinetics, safety, and tolerability of two sources of ch14.18 in pediatric patients with high-risk neuroblastoma following myeloablative therapy

K. Neville, F. Balis, Malcolm A. Smith, 2016, Cancer Chemotherapy and Pharmacology.

Phase I trial of fenretinide delivered orally in a novel organized lipid complex in patients with relapsed/refractory neuroblastoma: A report from the new approaches to neuroblastoma therapy (NANT) consortium

S. Groshen, J. Maris, K. Matthay, 2013, Pediatric blood & cancer.

The significance of serial histopathology in a residual mass for outcome of intermediate risk stage 3 neuroblastoma

K. Matthay, H. Shimada, R. Sposto, 2012, Pediatric blood & cancer.

Phase I Study of Vincristine, Irinotecan, and 131I-Metaiodobenzylguanidine for Patients with Relapsed or Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial

S. Groshen, R. Hawkins, J. Maris, 2012, Clinical Cancer Research.

Expression of neuroblastoma‐related genes in bone marrow at end of high‐risk neuroblastoma therapy

A. Naranjo, S. Asgharzadeh, R. Sposto, 2022, Pediatric blood & cancer.

Oxaliplatin and Doxorubicin for Relapsed or Refractory High-Risk Neuroblastoma

R. Jubran, L. Mascarenhas, A. Marachelian, 2015, Pediatric hematology and oncology.

Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma

Rachel A. Kudgus, S. Groshen, J. Maris, 2018, Clinical Cancer Research.

MIBG) for Patients with Relapsed or Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy (NANT) Trial

S. Groshen, R. Hawkins, J. Maris, 2012 .

Phase I study of vorinostat in combination with isotretinoin in patients with refractory/recurrent neuroblastoma: A new approaches to Neuroblastoma Therapy (NANT) trial

S. Groshen, K. Matthay, D. Haas-Kogan, 2018, Pediatric blood & cancer.

Phase I Study of Vorinostat as a Radiation Sensitizer with 131I-Metaiodobenzylguanidine (131I-MIBG) for Patients with Relapsed or Refractory Neuroblastoma

S. Groshen, R. Hawkins, K. Matthay, 2015, Clinical Cancer Research.

Forearm Skeletal Muscle Neuroblastoma in a Child: A Rare Primary Location

H. Shimada, T. Grikscheit, S. Giuliani, 2013, Journal of pediatric hematology/oncology.

Maintaining Outstanding Outcomes Using Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma: A Report From the Children's Oncology Group Study ANBL0531.

A. Naranjo, J. Gastier-Foster, J. Maris, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase I New Approaches to Neuroblastoma Therapy Study of Buthionine Sulfoximine and Melphalan With Autologous Stem Cells for Recurrent/Refractory High‐Risk Neuroblastoma

S. Groshen, J. Maris, K. Matthay, 2016, Pediatric blood & cancer.

Rare MYC-amplified Neuroblastoma With Large Cell Histology

J. Maris, H. Shimada, S. Asgharzadeh, 2018, Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society.

Predictors of outcome in children with Langerhans cell histiocytosis

R. Jubran, F. Dorey, A. Marachelian, 2005, Pediatric blood & cancer.

The Clinical Management and Outcomes of Pelvic Neuroblastic Tumors.

Eugene S. Kim, Larry L. Wang, A. Marachelian, 2020, The Journal of surgical research.

The clinical management and outcomes of cervical neuroblastic tumors.

Eugene S. Kim, H. Shimada, A. Marachelian, 2016, The Journal of surgical research.

Incidence and risk factors for secondary malignancy in patients with neuroblastoma after treatment with (131)I-metaiodobenzylguanidine.

J. Neuhaus, J. Maris, K. Matthay, 2016, European journal of cancer.

Treatment of primary CNS germinomatous germ cell tumors with chemotherapy prior to reduced dose whole ventricular and local boost irradiation

S. Khatua, F. Gilles, A. Panigrahy, 2010, Pediatric blood & cancer.

Premature epiphyseal growth plate arrest after isotretinoin therapy for high‐risk neuroblastoma: A case series and review of the literature

J. Villablanca, F. Goodarzian, A. Marachelian, 2020, Pediatric blood & cancer.

Predictors of response, progression‐free survival, and overall survival using NANT Response Criteria (v1.0) in relapsed and refractory high‐risk neuroblastoma

R. Hawkins, K. Matthay, H. Shimada, 2018, Pediatric blood & cancer.

Expression of Five Neuroblastoma Genes in Bone Marrow or Blood of Patients with Relapsed/Refractory Neuroblastoma Provides a New Biomarker for Disease and Prognosis

S. Groshen, K. Matthay, H. Shimada, 2017, Clinical Cancer Research.

The Role of Nursing Professionals in the Management of Patients With High-Risk Neuroblastoma Receiving Dinutuximab Therapy

K. Neville, S. Cohn, A. Marachelian, 2017, Journal of pediatric oncology nursing : official journal of the Association of Pediatric Oncology Nurses.

Cancer Therapy : Clinical Phase I Study of Vincristine , Irinotecan , and 131 I-Metaiodobenzylguanidine for Patients with Relapsed or Refractory Neuroblastoma : A New Approaches to Neuroblastoma Therapy Trial

S. Groshen, R. Hawkins, J. Maris, 2012 .

131I-metaiodobenzylguanidine with intensive chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma. A new approaches to neuroblastoma therapy (NANT) phase II study.

S. Groshen, R. Hawkins, J. Maris, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

and Autologous Stem Cell Transplantation for High-Risk Neuroblastoma. A New Approaches to Neuroblastoma Therapy (NANT) Phase II Study

S. Groshen, R. Hawkins, J. Maris, 2015 .

A phase I study of zoledronic acid and low‐dose cyclophosphamide in recurrent/refractory neuroblastoma: A new approaches to neuroblastoma therapy (NANT) study

S. Groshen, H. Daldrup-Link, K. Matthay, 2011, Pediatric blood & cancer.

Marrow-ablative chemotherapy followed by tandem autologous hematopoietic cell transplantation in pediatric patients with malignant brain tumors

J. Finlay, R. Sposto, G. Dhall, 2017, Bone Marrow Transplantation.

High‐dose chemotherapy and autologous hematopoietic progenitor cell rescue in children with recurrent medulloblastoma and supratentorial primitive neuroectodermal tumors

J. Finlay, A. Erdreich-Epstein, J. Villablanca, 2009, Cancer.

Infectious complications in the first year following autologous hematopoietic progenitor cell rescue for children with brain tumors

J. Finlay, G. Dhall, A. Butturini, 2013, Pediatric blood & cancer.

Myeloablative chemotherapy with autologous hematopoietic progenitor cell rescue for childhood central nervous system tumors

A. Butturini, A. Marachelian, J. Finlay, 2008, Bone Marrow Transplantation.